Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Yesterday, April 8, 2014, 48 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $150.00 to $9,683,280.00. Highlighted Stocks Traded by Insiders: CareFusion (CFN) - FREE Research Report Leonard Thomas J who is President, Medical Systems at CareFusion sold 1,250 shares at $40.05 on April 8, 2014. Following this transaction, the President, Medical Systems owned 35,803 shares meaning that the stake was reduced by 3.37% with the 1,250-share transaction. The shares most recently traded at $39.16, down $0.89, or 2.27% since the insider transaction. Historical insider transactions for CareFusion go as follows:
4-Week # shares sold: 1,250
12-Week # shares sold: 40,746
24-Week # shares sold: 104,496
The average volume for CareFusion has been 1.5 million shares per day over the past 30 days. CareFusion has a market cap of $8.3 billion and is part of the health care sector and health services industry. Shares are down 1.86% year-to-date as of the close of trading on Tuesday. CareFusion Corporation, a medical technology company, provides various healthcare products and services. It offers product lines in the areas of medication management, infection prevention, operating room effectiveness, respiratory care, and surveillance and analytics. The company has a P/E ratio of 24.5. Currently there are 5 analysts that rate CareFusion a buy, no analysts rate it a sell, and 6 rate it a hold. Exclusive Offer: Get the latest Stock Analysis on CFN - FREETheStreet Quant Ratings rates CareFusion as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full CareFusion Ratings Report from TheStreet Quant Ratings now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.